August 08, 2025

Neuroimaging Study Reveals SuperAging Brain Traits

Superagers aged 80 years and older demonstrate a unique neurobiological profile associated with successful aging: preserved memory and distinct brain anatomy, including thicker cortical regions and lower tau pathology.

Conexiant

August 08, 2025

How Many Vacation Days Are Doctors Taking?

A survey by the American Medical Association shows a rise in physicians taking time off, reflecting an improvement in burnout rates.

Conexiant

August 08, 2025

Mental Health Risk High in Patients with Hidradenitis Suppurativa

Hidradenitis suppurativa is associated with increased risks of depression and anxiety across all treatment levels, highlighting the importance of proactive psychiatric screening in dermatologic care.

Conexiant

July 31, 2025

Medical Oddities: Bubble Tea May Brew Burnout

From bubble tea to AI triage, small inputs had big impacts on mood, and memory.

Conexiant

August 07, 2025

Flu Treatment Linked to Lower Neuropsychiatric Risk in Pediatric and Adolescent Patients

Subgroup analyses demonstrated a greater reduction in neurologic events than psychiatric events, though the reduction in psychiatric events was not statistically significant.

Conexiant

August 06, 2025

Psilocybin Control Groups Show Lower Depression Gains

Researchers assess whether differences in control group outcomes across antidepressant trials reflect methodological variability, patient expectations, or limitations in blinding effectiveness.

Conexiant

August 06, 2025

UV Light Linked With Lower Respiratory Infection Rates 

Researchers found that germicidal UV light modestly reduced total respiratory infections in long-term care facilities for older adults.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant